These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors. Sampedro-Núñez M; Luque RM; Ramos-Levi AM; Gahete MD; Serrano-Somavilla A; Villa-Osaba A; Adrados M; Ibáñez-Costa A; Martín-Pérez E; Culler MD; Marazuela M; Castaño JP Oncotarget; 2016 Feb; 7(6):6593-608. PubMed ID: 26673010 [TBL] [Abstract][Full Text] [Related]
4. Peptides derived from the extracellular domain of the somatostatin receptor splicing variant SST5TMD4 increase malignancy in multiple cancer cell types. Del Rio-Moreno M; Alors-Perez E; Borges de Souza P; Prados-Gonzalez ME; CastaÑo JP; Luque RM; Gahete MD Transl Res; 2019 Sep; 211():147-160. PubMed ID: 30904441 [TBL] [Abstract][Full Text] [Related]
5. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Durán-Prado M; Gahete MD; Hergueta-Redondo M; Martínez-Fuentes AJ; Córdoba-Chacón J; Palacios J; Gracia-Navarro F; Moreno-Bueno G; Malagón MM; Luque RM; Castaño JP Oncogene; 2012 Apr; 31(16):2049-61. PubMed ID: 21927030 [TBL] [Abstract][Full Text] [Related]
8. The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. Gahete MD; Rincón-Fernández D; Durán-Prado M; Hergueta-Redondo M; Ibáñez-Costa A; Rojo-Sebastián A; Gracia-Navarro F; Culler MD; Casanovas O; Moreno-Bueno G; Luque RM; Castaño JP Oncotarget; 2016 Sep; 7(37):60110-60122. PubMed ID: 27507050 [TBL] [Abstract][Full Text] [Related]
9. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783 [TBL] [Abstract][Full Text] [Related]
10. Gonçalves CS; Vieira de Castro J; Pojo M; Martins EP; Queirós S; Chautard E; Taipa R; Pires MM; Pinto AA; Pardal F; Custódia C; Faria CC; Clara C; Reis RM; Sousa N; Costa BM Theranostics; 2018; 8(17):4805-4823. PubMed ID: 30279739 [TBL] [Abstract][Full Text] [Related]
11. The expression of the truncated isoform of somatostatin receptor subtype 5 associates with aggressiveness in medullary thyroid carcinoma cells. Molè D; Gentilin E; Ibañez-Costa A; Gagliano T; Gahete MD; Tagliati F; Rossi R; Pelizzo MR; Pansini G; Luque RM; Castaño JP; degli Uberti E; Zatelli MC Endocrine; 2015 Nov; 50(2):442-52. PubMed ID: 25854304 [TBL] [Abstract][Full Text] [Related]
12. The truncated isoform of somatostatin receptor5 (sst5TMD4) is associated with poorly differentiated thyroid cancer. Puig-Domingo M; Luque RM; Reverter JL; López-Sánchez LM; Gahete MD; Culler MD; Díaz-Soto G; Lomeña F; Squarcia M; Mate JL; Mora M; Fernández-Cruz L; Vidal O; Alastrué A; Balibrea J; Halperin I; Mauricio D; Castaño JP PLoS One; 2014; 9(1):e85527. PubMed ID: 24465589 [TBL] [Abstract][Full Text] [Related]
13. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. Liang Y; Bollen AW; Aldape KD; Gupta N BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952 [TBL] [Abstract][Full Text] [Related]
14. Functional genomics analyses of RNA-binding proteins reveal the splicing regulator SNRPB as an oncogenic candidate in glioblastoma. Correa BR; de Araujo PR; Qiao M; Burns SC; Chen C; Schlegel R; Agarwal S; Galante PA; Penalva LO Genome Biol; 2016 Jun; 17(1):125. PubMed ID: 27287018 [TBL] [Abstract][Full Text] [Related]
15. STAT-1 expression is regulated by IGFBP-3 in malignant glioma cells and is a strong predictor of poor survival in patients with glioblastoma. Thota B; Arimappamagan A; Kandavel T; Shastry AH; Pandey P; Chandramouli BA; Hegde AS; Kondaiah P; Santosh V J Neurosurg; 2014 Aug; 121(2):374-83. PubMed ID: 24878287 [TBL] [Abstract][Full Text] [Related]
16. EGFLAM correlates with cell proliferation, migration, invasion and poor prognosis in glioblastoma. Chen J; Zhang J; Hong L; Zhou Y Cancer Biomark; 2019; 24(3):343-350. PubMed ID: 30829611 [TBL] [Abstract][Full Text] [Related]
18. Expression and prognostic significance of TCTN1 in human glioblastoma. Meng D; Chen Y; Zhao Y; Wang J; Yun D; Yang S; Chen J; Chen H; Lu D J Transl Med; 2014 Oct; 12():288. PubMed ID: 25304031 [TBL] [Abstract][Full Text] [Related]
19. Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma. Se YB; Kim SH; Kim JY; Kim JE; Dho YS; Kim JW; Kim YH; Woo HG; Kim SH; Kang SH; Kim HJ; Kim TM; Lee ST; Choi SH; Park SH; Kim IH; Kim DG; Park CK Cancer Res Treat; 2017 Apr; 49(2):387-398. PubMed ID: 27456940 [TBL] [Abstract][Full Text] [Related]
20. Somatostatin, Cortistatin and Their Receptors Exert Antitumor Actions in Androgen-Independent Prostate Cancer Cells: Critical Role of Endogenous Cortistatin. Sáez-Martínez P; Porcel-Pastrana F; Pérez-Gómez JM; Pedraza-Arévalo S; Gómez-Gómez E; Jiménez-Vacas JM; Gahete MD; Luque RM Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361790 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]